Results 211 to 220 of about 791,804 (284)
Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert +2 more
wiley +1 more source
Fertility preservation in women with diminished ovarian reserve: evaluating the AMH criteria. [PDF]
Coccia ME +8 more
europepmc +1 more source
BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
Obianuju Sandra Madueke‐Laveaux +3 more
wiley +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Intraovarian Platelet-Rich Plasma for Women with Diminished Ovarian Reserve: A Systematic Review and Meta-Analysis. [PDF]
Wang X, Wei H, Du X, He H, Ma C.
europepmc +1 more source
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher +6 more
wiley +1 more source
Luteal-phase deficiency and diminished ovarian reserve: a narrative review of interactions and clinical implications. [PDF]
Zhang C, Gao M.
europepmc +1 more source
Diminished Ovarian Reserve in Women With Advanced Endometriosis
openaire +1 more source
Targeting KRAS for cancer therapy
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source

